The license agreement provides InxMed with right to use EZWi-Fit^® platform on the several novel ADC candidate molecules. InxMed will have the right for development, manufacturing, and commercialization of these ADC candidate molecules. 

InxMed is developing next generation TAAs targeting ADCs with significant improvement of efficacy and therapeutic window. Meanwhile, the company is developing solutions to boost ADC's efficacy including enhancing ADC penetration via FAK inhibitor and developing stroma targeting ADC to create synergy.

InxMed is positioned to invent next generation ADCs, with the attributes to be more tumor selective and potent, and broad combination potential. The novel antibodies discovered by InxMed to be equipped with payload from EZWi-Fit^®platform will be one of key differentiations.